Brad is a founding general partner of Treo Ventures.
He was Head of Johnson & Johnson Development Corporation (JJDC) from 2011 to 2015. JJDC is Johnson & Johnson’s venture investing arm and has offices in Silicon Valley, Boston, Shanghai, London and Tel Aviv. He established JJDC’s west coast office in 1997 and was an investor in medical devices, healthtech, and biotech for JNJ from 1992-2011. JJDC invests to support operating company interest in new technologies and also does venture investing to explore new technologies and business models. Brad successfully led the strategy for building a neuromodulation portfolio in the 2001-2015 era, and served on a number those company boards.
Prior to JJDC, Brad worked in preclinical surgery and product development at Ethicon, JNJ’s wound closure company, in projects to develop lasers, blood compatible polymers, wound healing stimulation, internal and external stapling and suture materials. Before joining JJDC he was part of JNJ’s Corporate Office of Science and Technology focused on surgical innovation and biomaterials for medical device applications.
He currently serves on a number of private company boards and one public board, Nevro, where he was an investor prior to the IPO. Brad led JJDC investments in a number of companies that were ultimately acquired by JNJ, including Biosense, Atrionix, and Indigo Medical.
Dr. Vale received a PhD in Biomedical Engineering from Iowa State University on the development of blood compatible polymers and a Doctor of Veterinary Medicine from Washington State University.